Oxalo Therapeutics is developing a novel drug to prevent recurrent kidney stones. Spun out from the University of Chicago, we use breakthrough discoveries from microbiome research to finally address an underlying cause of kidney stones. Every year kidney stones cause 1.3M+ ER visits and $10+ billion of healthcare costs. Most dangerously, they have a recurrence rate of ~70%. By focusing on prevention, we can end the debilitating pain and tremendous economic burden of this chronic disease.
Connect with Oxalo Therapeutics, Inc.